



To: AGO.highcostprescriptiondrugs@vermont.gov

From: Indivior Inc.
10710 Midlothian Turnpike
North Chesterfield, VA 23235

Re: New Drug Introduction Report Pursuant to 18 V.S.A. § 4637

To whom it may concern:

I write on behalf of Indivior Inc. (Indivior) to notify you, pursuant to 18 V.S.A. § 4637(b), regarding the introduction of a new prescription drug with a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program:

- PERSERIS (risperidone) extended-release injectable suspension, for subcutaneous use 90mg
- PERSERIS (risperidone) extended-release injectable suspension, for subcutaneous use 120mg

Further, pursuant to 18 V.S.A. § 4637(c), Indivior is providing the following information, which has been limited to that which is otherwise in the public domain or publicly available, as described in 18 V.S.A. § 4637(d):

(1) a description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally;

No information has been made publicly available at this time.

(2) the estimated volume of patients who may be prescribed the drug;

No information has been made publicly available at this time.

(3) whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval;

PERSERIS was not granted breakthrough therapy designation or priority review by the FDA prior to final approval.

(4) the date and price of acquisition if the drug was not developed by the manufacturer.

Not applicable.